Charles River CEO cites advantages of Chinese labor

Charles River Laboratories' $1.6 billion acquisition of China's WuXi PharmaTech positions the preclinical specialist to expand its contract work in drug discovery at a time that Big Pharma companies are consolidating and farming out a larger portion of their early-stage research work. And Charles River CEO makes it clear that the personnel in China who will be joining the company are one of the big attractions. "For some period of time, there'll be a wage benefit to using Chinese labor,'' CEO James C. Foster tells Boston Globe reporter Robert Weisman. "The labor is plentiful, cheaper, and better educated than in the States. It pains me to say so, but it's true.'' Story

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.